Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma Journal Article
| Authors: | von Tresckow, B.; Fanale, M.; Ardeshna, K. M.; Chen, R.; Meissner, J.; Morschhauser, F.; Moskowitz, C.; Zinzani, P. L.; Giezek, H.; Balakumaran, A.; Vo, T. T.; Raut, M.; Brice, P. |
| Article Title: | Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma |
| Abstract: | In KEYNOTE-087, pembrolizumab had a 69% overall response rate and acceptable safety in patients with relapsed/refractory classical Hodgkin lymphoma (rrHL). We assessed health-related quality of life (HRQoL) in KEYNOTE-087. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (QLQ-C30) and the EuroQoL Five Dimensions Questionnaire 3-level version (EQ-5D) were administered to 206 patients across three cohorts defined by lymphoma progression after: (1) autologous stem cell transplantation (ASCT) and subsequent brentuximab vedotin (BV) (n = 69); (2) salvage chemotherapy and BV (n = 79); and (3) ASCT without post-transplantation BV (n = 58). Compliance/completion rates were ≥90% at week 12 and ≥70% at week 24. QLQ-C30 global health status/QoL and EQ-5D visual analog scale scores showed mean increases from baseline in overall health at all assessed timepoints. With few exceptions, mean improvements from baseline to weeks 12 and 24 in QLQ-C30 functional and symptom scores occurred in all cohorts. Clinicaltrials.gov identifier: NCT02453594. © 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group. |
| Keywords: | adult; cancer chemotherapy; aged; major clinical study; chemotherapy; prospective study; quality of life; phase 2 clinical trial; cohort analysis; autologous stem cell transplantation; multicenter study; patient compliance; patient-reported outcomes; longitudinal study; classical hodgkin lymphoma; global health; patient-reported outcome; medication compliance; brentuximab vedotin; health-related quality-of-life; human; priority journal; article; pembrolizumab; european organization for research and treatment of cancer quality of life questionnaire core 30; european quality of life 5 dimensions questionnaire; keynote-087; european quality of life 5 dimensions visual analogue scale |
| Journal Title: | Leukemia and Lymphoma |
| Volume: | 60 |
| Issue: | 11 |
| ISSN: | 1042-8194 |
| Publisher: | Taylor & Francis Group |
| Date Published: | 2019-01-01 |
| Start Page: | 2705 |
| End Page: | 2711 |
| Language: | English |
| DOI: | 10.1080/10428194.2019.1602262 |
| PUBMED: | 31012356 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
